The C-peptide, also called the connecting peptide, is a 31-amino-acid polypeptide. It is secreted by pancreatic beta cells and is Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy often diagnosed at advanced stages, with carbohydrate antigen 19-9 (CA19-9) acting as the primary FDA-approved serum biomarker for management. Despite limitations, including false-positives in benign jaundice and false-negatives in Lewis-negative individuals, serial CA19-9 monitoring continues to be vital for staging & patient progress, and detecting early tumour recurrence.
Clinical Significance of CA19-9
Carbohydrate antigen 19-9 (CA19-9) is a tumour marker used to monitor pancreatic ductal adenocarcinoma (PDAC) and treatment response, and detect recurrence.
The primary clinical applications of CA19-9 include:
- Predicting Surgical Resection: Elevated CA19-9 levels (typically >100–300 U/mL) are strongly associated with subclinical metastatic disease, suggesting that the tumour is likely unresectable even when imaging appears reassuring.
- Tracking Treatment Response: Serial measurements are used to evaluate the patient’s degree of therapeutic response to neoadjuvant chemotherapy or radiation; a declining trend indicates therapeutic efficacy.
- Detecting Early Recurrence: Post-surgical monitoring can detect elevated CA19-9 levels months before structural tumours or metastases become visible on CT or MRI scans.
- Prognostic Stratification: Baseline and post-operative nadir (lowest) levels are independent predictors of overall patient survival.
Different Methods for CA19-9 Diagnosis:
Doctors recommend the CA19-9 Test to measure CA19-9 levels in serum or plasma. Normal CA19-9 levels vary depending on factors such as the individual’s age and sex. The standard normal reference range for CA19-9 in a healthy human body is 0 to 37 Units per millilitre (U/mL).
Conclusion In conclusion, the CA 19-9 test is an important laboratory investigation used mainly to support the evaluation and follow-up of pancreatic and other gastrointestinal diseases. It is particularly helpful in monitoring changes during treatment and observing the progression or recurrence of disease. However, an increased CA 19-9 level does not always indicate cancer because it may also occur in certain benign conditions. For this reason, the test result should be interpreted together with the patient’s symptoms, medical history, imaging findings, and other diagnostic tests. Overall, CA 19-9 is a useful marker for patient monitoring, but it should not be used alone to confirm a diagnosis.
Explore the Product…
